Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHA:688016)
China · Delayed Price · Currency is CNY 104.99
+1.00 (0.96%)
May 15, 2026, 9:45 AM CST
SHA:688016 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,389 | 1,350 | 1,203 | 1,187 | 896.5 | 684.63 |
Other Revenue | 0.14 | 0.14 | 3.67 | 0.01 | - | - |
| 1,389 | 1,351 | 1,206 | 1,187 | 896.5 | 684.63 | |
Revenue Growth (YoY) | 17.64% | 11.96% | 1.61% | 32.43% | 30.95% | 45.59% |
Cost of Revenue | 398.38 | 399.84 | 330.27 | 285.93 | 224.74 | 154 |
Gross Profit | 990.3 | 950.79 | 876.06 | 901.27 | 671.76 | 530.63 |
Selling, General & Admin | 289.53 | 290.25 | 250.25 | 185.19 | 150.02 | 103.81 |
Research & Development | 74.02 | 67.79 | 93.77 | 172.88 | 137.54 | 102.27 |
Other Operating Expenses | 0.61 | -0.24 | 6.58 | 7.5 | 8.3 | 5.32 |
Operating Expenses | 370.84 | 366.1 | 353.85 | 366.91 | 298.49 | 212.68 |
Operating Income | 619.46 | 584.69 | 522.21 | 534.36 | 373.27 | 317.95 |
Interest Expense | -1.35 | -2.16 | -1.65 | -1.82 | -2.09 | -1.77 |
Interest & Investment Income | 24.33 | 26.9 | 104.5 | 18.41 | 15.36 | 28.79 |
Currency Exchange Gain (Loss) | -4.47 | -4.47 | 1.59 | 1.19 | 2 | -0.44 |
Other Non Operating Income (Expenses) | -3.75 | -0.16 | -0.38 | -0.22 | -0.24 | -0.16 |
EBT Excluding Unusual Items | 634.22 | 604.8 | 626.26 | 551.92 | 388.29 | 344.38 |
Gain (Loss) on Sale of Investments | 0.37 | 0.37 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.1 | -0.09 | -0.7 | -0.1 | -0.23 | - |
Asset Writedown | -0.51 | - | - | - | - | - |
Other Unusual Items | 48.4 | 48.4 | 26.63 | 20.44 | 25.83 | 17.28 |
Pretax Income | 682.39 | 653.49 | 652.19 | 572.27 | 413.9 | 361.66 |
Income Tax Expense | 103.12 | 98.83 | 159.45 | 85.05 | 61.84 | 48.15 |
Earnings From Continuing Operations | 579.27 | 554.66 | 492.75 | 487.22 | 352.05 | 313.51 |
Minority Interest in Earnings | 9.26 | 8.67 | 9.35 | 5.21 | 4.83 | 2.34 |
Net Income | 588.53 | 563.33 | 502.1 | 492.43 | 356.88 | 315.86 |
Net Income to Common | 588.53 | 563.33 | 502.1 | 492.43 | 356.88 | 315.86 |
Net Income Growth | 31.53% | 12.19% | 1.96% | 37.98% | 12.99% | 47.17% |
Shares Outstanding (Basic) | 121 | 121 | 123 | 108 | 107 | 107 |
Shares Outstanding (Diluted) | 121 | 121 | 123 | 108 | 107 | 107 |
Shares Change (YoY) | -2.42% | -1.80% | 14.50% | 0.50% | 0.00% | -0.10% |
EPS (Basic) | 4.88 | 4.65 | 4.07 | 4.57 | 3.33 | 2.95 |
EPS (Diluted) | 4.88 | 4.65 | 4.07 | 4.57 | 3.33 | 2.95 |
EPS Growth | 34.80% | 14.25% | -10.95% | 37.30% | 12.99% | 47.32% |
Free Cash Flow | 311.93 | 270.03 | 160.95 | 368.05 | 39.78 | 210.67 |
Free Cash Flow Per Share | 2.59 | 2.23 | 1.30 | 3.42 | 0.37 | 1.97 |
Dividend Per Share | 2.300 | 2.300 | 2.012 | 2.013 | 1.544 | 1.409 |
Dividend Growth | 14.31% | 14.31% | -0.07% | 30.44% | 9.52% | 133.34% |
Gross Margin | 71.31% | 70.40% | 72.62% | 75.91% | 74.93% | 77.51% |
Operating Margin | 44.61% | 43.29% | 43.29% | 45.01% | 41.64% | 46.44% |
Profit Margin | 42.38% | 41.71% | 41.62% | 41.48% | 39.81% | 46.13% |
Free Cash Flow Margin | 22.46% | 19.99% | 13.34% | 31.00% | 4.44% | 30.77% |
EBITDA | 689.15 | 648.06 | 560.3 | 558.39 | 395.92 | 333.41 |
EBITDA Margin | 49.63% | 47.98% | 46.45% | 47.03% | 44.16% | 48.70% |
D&A For EBITDA | 69.7 | 63.38 | 38.1 | 24.03 | 22.65 | 15.46 |
EBIT | 619.46 | 584.69 | 522.21 | 534.36 | 373.27 | 317.95 |
EBIT Margin | 44.61% | 43.29% | 43.29% | 45.01% | 41.64% | 46.44% |
Effective Tax Rate | 15.11% | 15.12% | 24.45% | 14.86% | 14.94% | 13.31% |
Revenue as Reported | 1,389 | 1,351 | 1,206 | 1,187 | 896.5 | 684.63 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.